This is a working overview of Thymosin fraction 5, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-10 and is reviewed periodically as new material appears.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Cannibalism has two peaks in the life of a chicken; during the brooding period and at the onset of egg laying. The point-of-lay cannibalism is generally the most damaging and gets most of the attention. The temporary beak trimming developed at the Ohio Experiment Station assumed that cannibalism was a phase, and that blunting the beak temporarily would be adequate.
Reverse transport, or transporter reversal, is a phenomenon in which the substrates of a membrane transport protein are moved in the opposite direction to that of their typical movement by the transporter. Transporter reversal typically occurs when a membrane transport protein is phosphorylated by a particular protein kinase, which is an enzyme that adds a phosphate group to proteins.
The half-life, t1/2, is the time taken for the activity of a given amount of a radioactive substance to decay to half of its initial value. The decay constant, λ "lambda", the reciprocal of the mean lifetime (in s−1), sometimes referred to as simply decay rate. The mean lifetime, τ "tau", the average lifetime (1/e life) of a radioactive particle before decay. Although these are constants, they are associated with the statistical behavior of populations of atoms. In consequence, predictions using these constants are less accurate for minuscule samples of atoms. In principle a half-life, a third-life, or even a (1/√2)-life, could be used in exactly the same way as half-life; but the mean life and half-life t1/2 have been adopted as standard times associated with exponential decay. Those parameters can be related to the following time-dependent parameters:
Polyethyleneglycols are used in perfumes, cosmetics, pharmaceuticals, lubricants, paint thinners, and plasticizers. Ethylene glycol ethers are part of brake fluids, detergents, solvents, lacquers, and paints. Ethanolamines are used in the manufacture of soap and detergents and for purification of natural gas. Ethoxylates are reaction products of ethylene oxide with higher alcohols, acids, or amines. They are used in the manufacture of detergents, surfactants, emulsifiers, and dispersants. Whereas synthesis of ethylene glycols is the major application of ethylene oxide, its percentage varies greatly depending on the region: from 44% in the Western Europe, 63% in Japan, and 73% in North America to 90% in the rest of Asia, and 99% in Africa.
She trained at the London Academy of Music and Dramatic Art and her stage work has included appearances with the National Theatre and the Royal Shakespeare Company. She was made a dame in the 2020 Queen's Birthday Honours for services to charity, entertainment and the arts. David Littman (activist) (4 July 1933 – 20 May 2012) author of over five books and scores of monographs and academic papers and activist best known for organising the departure of Jewish children from Morocco; then worked as lobbyist at the United Nations in Geneva and was also historian. He was married to Bat Ye'or. Emanuel Litvinoff, novelist. (5 May 1915 – 24 September 2011) was a British writer and well-known figure in Anglo-Jewish literature, known for novels, short stories, poetry, plays and human rights campaigning. Litvinoff became aware of plight of persecuted Soviet Jews, and started worldwide campaign against this persecution. Due to Litvinoff's efforts, prominent Jewish groups in United States became aware of issue, and well-being of Soviet Jews became cause for a worldwide campaign, eventually leading to mass migration of Jews from the Soviet Union to Israel and the United States. For this he has been described by Meir Rosenne, former Israeli ambassador to the United States, as "one of the greatest unsung heroes of the twentieth century... who won in the fight against an evil empire" and that "thousands and thousands of Russian Jews owe him their freedom".
Sources: en.wikipedia.org
The milky sap of Calotropis plants is a toxic substance that can cause irritation when it comes into contact with the skin or eyes. The sap can be collected from various parts of the plant, including the flowers, stem, and leaves. The sap is extremely bitter and turns into a gluey coating that is resistant to soap, therefore it has to be treated immediately once it has fallen into the eye. Calotropis species are toxic plants; calotropin, a compound in the latex, is more toxic than strychnine. Calotropin is similar in structure to two cardiac glycosides which are responsible for the cytotoxicity of Apocynum cannabinum. Extracts from the flowers of Calotropis procera have shown strong cytotoxic activity. Cattle and other animals often stay away from the plants because of their unpleasant taste and their content of cardiac glycosides. The toxic ingredients of Calotropis plants, including Calotropis procera, can be preserved in liquid form, and they naturally disintegrate over time. Calotropis leaves are used as fodder for animals once they are dried.
dihydrothymine dehydrogenase dihydrouracil dehydrogenase (NADP+) 4,5-dihydrothymine: oxidoreductase DPD DHPDH dehydrogenase, dihydrouracil (nicotinamide adenine dinucleotide, phosphate) DHU dehydrogenase hydropyrimidine dehydrogenase dihydropyrimidine dehydrogenase (NADP+)
Streptomycin is an antibiotic medication used to treat a number of bacterial infections, including tuberculosis, Mycobacterium avium complex, endocarditis, brucellosis, Burkholderia infection, plague, tularemia, and rat bite fever. For active tuberculosis it is often given together with isoniazid, rifampicin, and pyrazinamide. It is administered by injection into a vein or muscle. Common side effects include vertigo, vomiting, numbness of the face, fever, and rash. Use during pregnancy may result in permanent deafness in the developing baby. Use appears to be safe while breastfeeding. It is not recommended in people with myasthenia gravis or other neuromuscular disorders. Streptomycin is an aminoglycoside. It works by blocking the ability of 30S ribosomal subunits to make proteins, which results in bacterial death. Albert Schatz first isolated streptomycin in 1943 from Streptomyces griseus. It is on the World Health Organization's List of Essential Medicines. The World Health Organization classifies it as critically important for human medicine.
Undernutrition adversely affects the cognitive development of children, contributing to poor earning capacity and poverty in adulthood. The development of childhood undernutrition coincides with the introduction of complementary weaning foods which are usually nutrient deficient. The World Health Organization estimated in 2008 that malnutrition accounted for 54 percent of child mortality worldwide, about 1 million children. There is a strong association between undernutrition and child mortality. Another estimate in 2008 also by WHO stated that childhood underweight was the cause for about 35% of all deaths of children under the age of five years worldwide. Over 90% of the stunted children below five years of age live in sub-Saharan Africa and South Central Asia. Although access to adequate food and improving nutritional intake is an obvious solution to tackling undernutrition in children, the progress in reducing children undernutrition has been disappointing.
Sources: en.wikipedia.org
Beyond anthraquinones, X. parietina contains additional pigments, including carotenoids such as mutatoxanthin, which contribute to its photoprotective capabilities. The total carotenoid content in X. parietina can reach up to 94.7 mg/g dry weight, significantly higher than in some related species, indicating a strong investment in light protection mechanisms. Furthermore, the synthesis of anthraquinones in X. parietina is linked to its symbiotic relationship with Trebouxia algae—ribitol, a carbohydrate supplied by the photobiont, has been shown to significantly enhance parietin production when provided in culture.
Gregory L. Verdine (born June 10, 1959) is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability. Verdine is the co-inventor with Christian Schafmeister of stapled peptides, a new class of drugs that combines the versatile binding properties of monoclonal antibodies with the cell-penetrating ability of small molecules. Verdine coined the term "drugging the undruggable" to describe the unique capabilities of stapled peptides. A close analog of a stapled peptide drug invented in the Verdine Lab, sulanemadlin (ALRN-6924), is a first-in-class dual MDM2/MDMX inhibitor currently in Phase II clinical development by Aileron Therapeutics, which he co-founded in 2005. FogPharma, founded in 2016, aims to further develop stapled peptide technology for therapeutic use. He has founded numerous other drug discovery companies, including six that are listed on the NASDAQ. His companies have succeeded in developing two FDA-approved drugs, romidepsin and paritaprevir, which are, respectively, an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs), and an acylsulfonamide inhibitor that is used to treat chronic hepatitis C.
Turin is well known for its chocolate production, especially for its traditional, ingot-shaped chocolate called gianduiotto, named after Gianduja, a local commedia dell'arte mask. Moreover, the city is also known for the so-called bicerin, a traditional hot drink made of espresso, drinking chocolate and whole milk served layered in a small rounded glass. Every year Turin organises CioccolaTÒ, a two-week chocolate festival run with the main Piedmontese chocolate producers, such as Caffarel, Streglio, Venchi and others, as well as some big international companies, such as Lindt & Sprüngli.
=== 4 March === Ukrainian forces reportedly began their withdrawal from Bakhmut and reports stated that many civilians fled from the city. Rheinmetall, a German military vehicle and weapons manufacturing company, is reported to be negotiating with the government of Ukraine about the possibility of building a tank factory in Ukraine. The proposed factory would cost about 200 million euros and be capable of producing up to 400 Panther KF51 tanks per year. Armin Papperger, the CEO, reportedly argues that Ukraine would need about 600 to 800 new tanks to win the war, which is more than the 300 existing tanks that Germany could supply them with. The Ukrainian Defence Minister, Oleksiy Reznikov, wrote a letter to the European Union asking for 250,000 155mm shells per month. Ukrainian forces use approximately 110,000 155mm shells per month. He claimed that Ukrainian forces were only firing a fifth of what they could due to shortages. The Ukrainian hope is to use "594,000" shells per month. NATO is considering establishing factories in Eastern Europe to increase production of Soviet era ammunition.
Heparin is given parenterally because it is not absorbed from the gut, due to its high negative charge and large size. It can be injected intravenously or subcutaneously (under the skin); intramuscular injections (into muscle) are avoided because of the potential for forming hematomas. Because of its short biologic half-life of about one hour, heparin must be given frequently or as a continuous infusion. Unfractionated heparin has a half-life of about one to two hours after infusion, whereas LMWH has a half-life of four to five hours. The use of LMWH has allowed once-daily dosing, thus not requiring a continuous infusion of the drug. If long-term anticoagulation is required, heparin is often used only to commence anticoagulation therapy until an oral anticoagulant e.g. warfarin takes effect. The American College of Chest Physicians publishes clinical guidelines on heparin dosing.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.